therapeutic innovation & regulatory science

contemporary clinical trials

journal of bioethical inquiry

public health reports (washington, dc : 1974)

pda journal of pharmaceutical science and technology

journal of community hospital internal medicine perspectives

[1] The knowledge, concerns and healthcare practices among physicians regarding electronic cigarettes.

[2] Pharmaceutical Ethics and Grassroots Activism in the United States: A Social History Perspective.

[3] Awareness of "The Real Cost" Campaign Among US Middle and High School Students: National Youth Tobacco Survey, 2017.

[4] How Do Drug Regulatory Bodies Deal With Potential Innovative Therapies?

[5] one and done: reasons principal investigators conduct only one fda-regulated drug trial

[6] validation of the oxford participation and activities questionnaire

[7] overseeded of oat cultivars in grazing african star with different wastes managed forage<br>sobressemeadura de cultivares de aveia em pastagem de estrelaafricana manejada com diferentes resíduos de forragem

[8] postmarketing commitments for novel drugs and biologics approved by the us food and drug administration: a cross-sectional analysis

[9] a method to determine the kink resistance of stents and stent delivery systems according to international standards

[10] A new zeolitic hydroxymethylimidazolate material and its use in mixed matrix membranes based on 6FDA-DAM for gas separation

[11] Pediatric drugs - good but too expensive: Appeal to the FDA and the manufacturers

[12] A survey of informed consents from FDA's center for devices and radiological health.

[13] Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing.

[14] Generating a Health Information Technology Event Database from FDA MAUDE Reports.

[15] The History of the FDA's Fight for Consumer Protection and Public Health, by US Food and Drug Administration.

[16] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.

[17] Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.

[18] Why do people use food delivery apps (FDA)? A uses and gratification theory perspective

[19] Use of FDA-Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic.

[20] FDA commissioner Gottlieb resigns

[21] FDA Regulatory Concerns for Wound Healing Biologics

[22] American Epilepsy Society (AES): Written Comments to Norman E. “Ned” Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019

[23] The FDA Changed Everything.

[24] Spectral signal processing approaches for selective quantification of the recently FDA approved brand-new combination of Vaborbactam and Meropenem; for conformity assessment of bulk and batch release

[25] The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.

[26] Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease

[27] Ten years post-GAO assessment, FDA remains uninformed of potentially harmful GRAS substances in foods.

[28] Adverse drug event detection using reason assignments in FDA drug labels.

[29] Global Regulatory Review Needed for Cochlear Implants: A Call for FDA Leadership.

[30] FDA-Approved Medications to Treat Tardive Dyskinesia

[31] one and done: reasons principal investigators conduct only one fda-regulated drug trial

[32] virtual screening of fda-approved drugs against lasr of <i>pseudomonas aeruginosa</i> for antibiofilm potential

[33] future challenges and opportunities in online prescription drug promotion research; comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of fda warning letters”

[34] repositioning fda drugs as potential cruzain inhibitors from trypanosoma cruzi: virtual screening, in vitro and in vivo studies

[35] A New Anti-Estrogen Discovery Platform Identifies FDA-Approved Imidazole Anti-Fungal Drugs as Bioactive Compounds against ERα Expressing Breast Cancer Cells.

[36] 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)

[37] 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)

[38] Al-Malik al-Afḍal al-ʿAbbās b. ʿAlī b. Dāwūd al-Rasūlī, Bughyat al-fallāḥīn fī al-ashjār al-muthmira wa-l-rayāḥīn

[39] Patients see proposed FDA opioid rules as painfully restrictive